NCT06776952View on ClinicalTrials.gov

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

April 30, 2028

Conditions
Relapsed/Refractory Peripheral T Cell Lymphoma
Interventions
DRUG

XNW5004 ; Chidamide placebo

XNW5004 + Chidamide placebo

DRUG

XNW5004 placebo; Chidamide

XNW5004 placebo + Chidamide

Sponsors
All Listed Sponsors
lead

Evopoint Biosciences Inc.

INDUSTRY